comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 01:36:47 - browse：735

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FDA reorg will put new emphasis on investigations, sources say

hotspot

WSS

Publishing genetic code of viruses could cause disaster

What is STAT's opinion section for?

Medicare’s new pay boost for primary care is angering specialists

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Digital health: a case of mistaken identity

A letter from the executive editor: STAT UnitedHealth investigation

entertainment

comprehensive

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA reorg will put new emphasis on investigations, sources say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: More tumult at BIO & coercive care for sickle cell patients

Trump demands the U.S. pay no more for drugs than other countries … again

What health policies could hitch a ride on a spending bill?

Hepatitis C has a cure — but many Americans still lack access to it

H5N1 virus can be tracked in retail milk, scientists say

State Dept. review finds Biden bears some blame for Afghanistan failures

Addressing health care workers' trauma can help fight burnout

entertainment

H5N1 bird flu outbreak: Second human case reported, in Michigan

FDA poised to publish guidelines for clinical trial diversity

Study suggests Covid rebound is far more common with Paxlovid than without

First transplant of an entire human eye performed

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Study suggests Covid rebound is far more common with Paxlovid than without

Wikipedia

knowledge

hotspot

hotspot